182 related articles for article (PubMed ID: 27816557)
1. Influence of magnesium supplementation on movement side effects related to typical antipsychotic treatment in rats.
Kronbauer M; Metz VG; Roversi K; Dias VT; de David Antoniazzi CT; da Silva Barcelos RC; Burger ME
Behav Brain Res; 2017 Mar; 320():400-411. PubMed ID: 27816557
[TBL] [Abstract][Full Text] [Related]
2. Influence of magnesium supplementation and L-type calcium channel blocker on haloperidol-induced movement disturbances.
Kronbauer M; Metz VG; Roversi K; Milanesi LH; Rubert Rossato D; da Silva Barcelos RC; Burger ME
Behav Brain Res; 2019 Nov; 374():112119. PubMed ID: 31374223
[TBL] [Abstract][Full Text] [Related]
3. Magnesium Supplementation Prevents and Reverses Experimentally Induced Movement Disturbances in Rats: Biochemical and Behavioral Parameters.
Kronbauer M; Segat HJ; De David Antoniazzi CT; Roversi K; Roversi K; Pase CS; Barcelos RC; Burger ME
Biol Trace Elem Res; 2015 Aug; 166(2):163-72. PubMed ID: 25686766
[TBL] [Abstract][Full Text] [Related]
4. Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract.
Trevizol F; Benvegnú DM; Barcelos RC; Pase CS; Segat HJ; Dias VT; Dolci GS; Boufleur N; Reckziegel P; Bürger ME
Behav Brain Res; 2011 Aug; 221(1):13-8. PubMed ID: 21356248
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats.
Dhingra D; Goswami S; Gahalain N
Nutr Neurosci; 2018 Nov; 21(9):667-675. PubMed ID: 28641484
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Tada M; Shirakawa K; Matsuoka N; Mutoh S
Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
[TBL] [Abstract][Full Text] [Related]
7. B vitamins attenuate haloperidol-induced orofacial dyskinesia in rats: possible involvement of antioxidant mechanisms.
Macêdo DS; Oliveira GV; Gomes PX; Araújo FY; Souza CM; Vasconcelos SM; Viana GS; Sousa FC; Carvalho AF
Behav Pharmacol; 2011 Oct; 22(7):674-80. PubMed ID: 21918383
[TBL] [Abstract][Full Text] [Related]
8. The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes.
Erosa-Rivero HB; Bata-García JL; Alvarez-Cervera FJ; Heredia-López FJ; Góngora-Alfaro JL
Neuropharmacology; 2014 Jun; 81():176-87. PubMed ID: 24534110
[TBL] [Abstract][Full Text] [Related]
9. Effects of tryptophan and valine administration on behavioral pharmacology of haloperidol.
Ali O; Haleem DJ; Saify ZS; Kamil N; Obaid R; Ahmed SW
Pak J Pharm Sci; 2005 Apr; 18(2):23-8. PubMed ID: 16431394
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice.
Sonego AB; Gomes FV; Del Bel EA; Guimaraes FS
Behav Brain Res; 2016 Aug; 309():22-8. PubMed ID: 27131780
[TBL] [Abstract][Full Text] [Related]
11. Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter.
Barcelos RC; Benvegnú DM; Boufleur N; Reckziegel P; Müller LG; Pase C; Emanuelli T; Bürger ME
Neurotox Res; 2010 Apr; 17(3):228-37. PubMed ID: 19644727
[TBL] [Abstract][Full Text] [Related]
12. [Effects of risperidone on catalepsy and cerebral dopamine, serotonin and GABA metabolism in the rat: comparison with haloperidol].
Kikumoto O; Okamoto Y; Hayakawa H; Yokota N; Kawai K; Motohashi N; Yamawaki S
Yakubutsu Seishin Kodo; 1993 Feb; 13(1):39-42. PubMed ID: 7686319
[TBL] [Abstract][Full Text] [Related]
13. Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats.
Thaakur S; Himabindhu G
J Neural Transm (Vienna); 2009 Jul; 116(7):807-14. PubMed ID: 19444377
[TBL] [Abstract][Full Text] [Related]
14. Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.
Hyde TM; Egan MF; Wing LL; Wyatt RJ; Weinberger DR; Kleinman JE
Psychopharmacology (Berl); 1995 Mar; 118(2):142-9. PubMed ID: 7617800
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
[TBL] [Abstract][Full Text] [Related]
16. Haloperidol-induced catalepsy is influenced by calcium channel antagonists.
Biała G
Acta Pol Pharm; 2000; 57(3):233-7. PubMed ID: 11143713
[TBL] [Abstract][Full Text] [Related]
17. Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia.
Wang MH; Yang CC; Tseng HC; Fang CH; Lin YW; Soung HS
Neurotox Res; 2021 Jun; 39(3):774-786. PubMed ID: 33523404
[TBL] [Abstract][Full Text] [Related]
18. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
[TBL] [Abstract][Full Text] [Related]
19. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
[TBL] [Abstract][Full Text] [Related]
20. Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence.
Wadenberg ML; Wiker C; Svensson TH
Int J Neuropsychopharmacol; 2007 Apr; 10(2):191-202. PubMed ID: 16707032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
